Allergan Aesthetics’ Carrie Strom on the ‘aesthetics generation’ and new frontiers for injectables

10 months ago 20

Subscribe: Apple Podcasts • Stitcher • Google Play • Spotify

Botox has dominated the neurotoxin market since its FDA approval for cosmetic use in 2002. However, its iconic status would not be possible without the backing of global company Allergan Aesthetics.

In addition to Botox, Allergan Aesthetics itself a subsidiary of pharmaceutical company AbbVie, which houses aesthetics brands including Juvéderm, SkinVive, Kybella and Coolsculpting, among others. In its full-year 2023 earnings released in February, AbbVie reported that the global net revenue of its aesthetics portfolio was about $5.3 billion, with global Botox Cosmetic’s net revenue reaching $2.7 billion and global Juvéderm’s net revenue equalling $1.4 billion. Leading this portfolio of aesthetics products, and guiding the future of the aesthetics industry, is Carrie Strom, svp of AbbVie and Global Allergan Aesthetics president.

Continue reading this article on glossy.co. Sign up for Glossy newsletters to get the latest on the business of beauty, fashion and pop culture.

Article From: www.glossy.co

Read Entire Article

Note:

We invite you to explore our website, engage with our content, and become part of our community. Thank you for trusting us as your go-to destination for news that matters.

Certain articles, images, or other media on this website may be sourced from external contributors, agencies, or organizations. In such cases, we make every effort to provide proper attribution, acknowledging the original source of the content.

If you believe that your copyrighted work has been used on our site in a way that constitutes copyright infringement, please contact us promptly. We are committed to addressing and rectifying any such instances

To remove this article:
Removal Request